Traders should monitor EU launch execution and national reimbursement outcomes, particularly in Germany, as these will drive revenue contribution. The approval strengthens Pharming's global commercial footprint and reduces geographic concentration risk.
PHAR drugs
PHAR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $13.62entry
- T+1 · 6mo ago −1.54%α −1.55% · $13.41
- T+5 · 6mo ago −9.84%α −11.05% · $12.28
- T+20 · 5mo ago −4.48%α −2.53% · $13.01
- T+60 · 3mo ago −13.00%α −15.72% · $11.85
Price Chart
How similar events traded
Executive Summary
Pharming announces that the European Commission has granted marketing authorization for Joenja (leniolisib) as the first approved treatment for APDS in the EU. The first European launch is expected in Germany in Q3 2026, expanding Joenja's market to 27 EU member states plus Norway, Iceland, and Liechtenstein.
Key Facts
- European Commission granted marketing authorization for Joenja (leniolisib) for APDS in adult and pediatric patients 12 years and older.
- First and only approved treatment for APDS in the European Union.
- First European launch expected in Germany in Q3 2026, with additional launches pending national reimbursement negotiations.
- Approval valid across all 27 EU member states, plus Norway, Iceland, and Liechtenstein.
- Joenja is already approved in the United States, United Kingdom, Japan, Australia, and Israel.
Financial Impact
Expands Joenja's addressable market to EU27+3 countries; initial launch in Germany expected Q3 2026. No financial terms disclosed.
Risk Factors
- Reimbursement negotiations may delay or limit market access in some EU countries.
- Potential competition from future APDS therapies.
- Currency and foreign exchange risks from international revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000027 |
| Document: 0001828316-26-000027-index-headers.html | 0001828316-26-000027 |
| Document: 0001828316-26-000027-index.html | 0001828316-26-000027 |
| Document: 0001828316-26-000027.txt | 0001828316-26-000027 |
Track record
18 reports on PHAR
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Oct 27, 202620d ago 6-K Bullish 6/10 No price data
- Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
- Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
- Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
- Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers